Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.16 USD

94.16
1,891,045

-0.30 (-0.32%)

Updated Jul 12, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

Align (ALGN) Gains From New Launches, Strategic Partnerships

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

STERIS' (STE) Improved Volume, New Buyouts Drive Growth

On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.

PetMeds (PETS) to Advance Pet Care With New Collaboration

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

PacBio's (PACB) New Offering to Boost WGS Data Analysis

PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.

3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.

Zacks.com featured highlights Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland

Rev Group, CVR Energy, Cardinal Health, Commercial Vehicle and Archer Daniels Midland have been highlighted in this Screen of The Week article.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.

Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Maharathi Basu headshot

5 Stocks That Brokers Favor Despite the Ongoing Uncertainty

We believe that stocks like Rev Group (REVG), CVR Energy (CVI), Cardinal Health (CAH), Commercial Vehicle Group (CVGI) and Archer Daniels (ADM) should be on an investor's watchlist.

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.

Globus Medical (GMED) Gains From NuVasive Buyout, Innovation

Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease

Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.

Alcon (ALC) Gains From Growing Market Demand, New Launches

Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.

Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships

Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.

Haemonetics (HAE) Announces Agreement to Acquire OpSens

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.